BRIEF published on 04/10/2025 at 19:05, 11 months 28 days ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 11 months 28 days ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year 1 month ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year 1 month ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year 2 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 2 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 3 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/04/2024 at 19:55, 1 year 4 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 4 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 4 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
Published on 04/09/2026 at 16:00, 2 hours 53 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 4 hours 13 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 4 hours 53 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 5 hours 23 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 13:30, 5 hours 23 minutes ago ESGold Advances Toward Production and Exploration Drilling as Mill Buildout Progresses in Parallel
Published on 04/09/2026 at 18:15, 38 minutes ago REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:40, 3 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 3 hours 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 18:35, 18 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 15:57, 2 hours 56 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 11 hours 53 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
